74 related articles for article (PubMed ID: 19387990)
1. Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus.
Tamura M; Shiba S; Kudo N; Kawashima Y
Chirality; 2010 Jan; 22(1):92-8. PubMed ID: 19387990
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
Inoue T; Shibahara N; Miyagawa K; Itahana R; Izumi M; Nakanishi T; Takamitsu Y
Clin Nephrol; 2003 Aug; 60(2):90-5. PubMed ID: 12940610
[TBL] [Abstract][Full Text] [Related]
3. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of nateglinide in humans.
Weaver ML; Orwig BA; Rodriguez LC; Graham ED; Chin JA; Shapiro MJ; McLeod JF; Mangold JB
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):415-21. PubMed ID: 11259325
[TBL] [Abstract][Full Text] [Related]
5. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
[TBL] [Abstract][Full Text] [Related]
6. Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet.
Mine T; Miura K; Kajioka T; Kitahara Y
Metabolism; 2008 Jan; 57(1):140-8. PubMed ID: 18078871
[TBL] [Abstract][Full Text] [Related]
7. Nateglinide (Starlix): update on a new antidiabetic agent.
Phillips LS; Dunning BE
Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
[TBL] [Abstract][Full Text] [Related]
8. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography.
Bengel FM; Abletshauser C; Neverve J; Schnell O; Nekolla SG; Standl E; Schwaiger M
Diabet Med; 2005 Feb; 22(2):158-63. PubMed ID: 15660732
[TBL] [Abstract][Full Text] [Related]
9. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
10. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.
Choudhury S; Hirschberg Y; Filipek R; Lasseter K; McLeod JF
J Clin Pharmacol; 2000 Jun; 40(6):634-40. PubMed ID: 10868314
[TBL] [Abstract][Full Text] [Related]
11. [Nateglinide].
Notoya Y; Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
[No Abstract] [Full Text] [Related]
12. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
13. Insulin and nateglinide reduce monocyte adhesion to endothelial cells in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
Tanaka A; Azuma K; Toyofuku Y; Kurokawa A; Otsuka A; Mita T; Hirosea T; Fujitani Y; Miyauchi K; Daida H; Kawamori R; Watada H
Biochem Biophys Res Commun; 2006 Nov; 350(1):195-201. PubMed ID: 16997277
[TBL] [Abstract][Full Text] [Related]
14. Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes.
Schrijvers BF; De Vriese AS; Van de Voorde J; Rasch R; Lameire NH; Flyvbjerg A
Nephrol Dial Transplant; 2004 May; 19(5):1092-7. PubMed ID: 14993490
[TBL] [Abstract][Full Text] [Related]
15. Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent.
Takesada H; Matsuda K; Ohtake R; Mihara R; Ono I; Tanaka K; Naito M; Yatagai M; Suzuki E
Bioorg Med Chem; 1996 Oct; 4(10):1771-81. PubMed ID: 8931947
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a stereoselective HPLC method for the determination of the in vitro transport of nateglinide enantiomers in rat intestine.
Maddi S; Keshetty S; Mohan Ega C; Yamasani MR; Scriba GK
J Sep Sci; 2007 Aug; 30(12):1875-80. PubMed ID: 17638349
[TBL] [Abstract][Full Text] [Related]
17. Senaglinide. A 4166, AY 4166, Fastic, SDZ DJN 608, Starlix, Starsis, YM 026, Nateglinide.
Drugs R D; 1999 Aug; 2(2):123-6. PubMed ID: 10820657
[No Abstract] [Full Text] [Related]
18. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
[TBL] [Abstract][Full Text] [Related]
19. Nateglinide therapy for type 2 diabetes mellitus.
Levien TL; Baker DE; Campbell RK; White JR
Ann Pharmacother; 2001 Nov; 35(11):1426-34. PubMed ID: 11724096
[TBL] [Abstract][Full Text] [Related]
20. Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.
Kitahara Y; Miura K; Takesue K; Mine T; Wada R; Uchida Y; Ito S; Yagihashi S
Metabolism; 2002 Nov; 51(11):1452-7. PubMed ID: 12404197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
